Welcome to our dedicated page for Orgenesis SEC filings (Ticker: ORGS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to Orgenesis Inc. (ORGS) SEC filings, offering detailed insight into the company’s financial condition, risk profile, and material agreements. As a global biotech company focused on cell and gene therapies (CGTs) and decentralized cell processing, Orgenesis uses its periodic reports and current reports to describe how it funds and operates its platforms, subsidiaries, and therapeutic programs.
Through annual reports on Form 10-K and quarterly reports on Form 10-Q, readers can review audited and interim financial statements, including revenues, operating losses, capital deficiency, liabilities, and cash balances. These filings also contain management’s discussion and analysis and a "Risk Factors" section that discusses issues such as reliance on the point-of-care cell therapy platform and OMPUL business, dependence on third parties, the need for additional capital, and competitive and regulatory challenges.
Current reports on Form 8-K highlight specific material events. For example, Orgenesis has filed 8-Ks describing a 1-for-10 reverse stock split, the transition of its common stock from Nasdaq to the OTCQX Best Market, equity and collaboration financings, and a Convertible Loan Agreement entered into by Theracell Laboratories IKE, an indirect subsidiary. That agreement includes an initial loan, a credit facility, potential conversion into equity of Orgenesis or Theracell, associated warrants, and the lender’s right, subject to approvals, to appoint members to Orgenesis’ Board of Directors, along with security interests over certain assets.
On Stock Titan, Orgenesis filings are updated in near real time as they appear on EDGAR. AI-powered summaries help explain the key points of lengthy documents such as 10-Ks and 10-Qs, highlight important terms in 8-Ks, and clarify the implications of complex financing structures and capital changes. Users can also review insider-related information disclosed in forms and exhibits, while AI analysis surfaces the sections most relevant to capital structure, liquidity, risk disclosures, and strategic transactions for a clearer view of ORGS from its official regulatory record.
Orgenesis Inc. reported issuing an Alpha Warrant to Alpha Prosperity Fund SPC in connection with a previously agreed convertible loan and credit facility. The warrant relates to the first $1,000,000 drawdown under a $1,000,000 convertible loan and $10,000,000 credit facility and is exercisable for 3,289,490 shares of common stock for an aggregate exercise price of $250,000 over three years. The company states that the Alpha Warrant and the shares issuable upon exercise were issued without registration under the Securities Act, relying on the Section 4(a)(2) exemption for transactions not involving a public offering.
Orgenesis Inc. entered into a Convertible Loan Agreement through its subsidiary Theracell Laboratories IKE with Alpha Prosperity Fund SPC. The lender is providing an initial
After 30 days and until maturity, the lender can choose to convert the outstanding amount into equity of either Orgenesis or Theracell so that it would hold up to